When did HERON THERAPEUTICS INC (HRTX) report earnings last quarter?
HERON THERAPEUTICS INC (HRTX) last reported earnings on 2/26/2026.
NASDAQ:HRTX • US4277461020
Past quarterly earnings results for HERON THERAPEUTICS INC (HRTX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.02 | -0.02 | 1.96% | -200.00% | 40.588M | 40.324M | 0.65% | -0.47% |
| Q3 2025 | -0.04 | -0.02 | -161.44% | -33.33% | 38.213M | 39.812M | -4.02% | 16.47% |
| Q2 2025 | -0.02 | -0.01 | -96.08% | 66.67% | 37.2M | 38.837M | -4.22% | 3.26% |
| Q1 2025 | 0.01 | -0.01 | 246.99% | 150.00% | 38.903M | 38.165M | 1.93% | 12.21% |
| Q4 2024 | 0.02 | -0.03 | 173.52% | 128.57% | 40.781M | 38.114M | 7.00% | 19.13% |
| Q3 2024 | -0.03 | -0.03 | 11.76% | 82.35% | 32.81M | 37.672M | -12.91% | 4.38% |
| Q2 2024 | -0.06 | -0.04 | -47.06% | 82.86% | 36.024M | 36.605M | -1.59% | 13.42% |
| Q1 2024 | -0.02 | -0.09 | 78.21% | 92.59% | 34.67M | 33.635M | 3.08% | 17.07% |
| Q4 2023 | -0.07 | -0.17 | 58.07% | 58.82% | 34.233M | 31.595M | 8.35% | 14.00% |
| Q3 2023 | -0.17 | -0.30 | 43.02% | 55.26% | 31.434M | 33.303M | -5.61% | 18.35% |
| Q2 2023 | -0.35 | -0.24 | -47.02% | 36.36% | 31.762M | 32.33M | -1.76% | 14.95% |
| Q1 2023 | -0.27 | -0.21 | -30.40% | 57.14% | 29.615M | 30.281M | -2.20% | 26.24% |
| Q4 2022 | -0.17 | -0.29 | 41.52% | 68.52% | 30.03M | 27.435M | 9.46% | 45.35% |
| Q3 2022 | -0.38 | -0.38 | 0.92% | 25.49% | 26.56M | 27.499M | -3.41% | 14.33% |
| Q2 2022 | -0.55 | -0.52 | -6.78% | 11.29% | 27.63M | 25.39M | 8.82% | 23.13% |
| Q1 2022 | -0.63 | -0.49 | -29.76% | -8.62% | 23.46M | 23.058M | 1.74% | 17.18% |
| Q4 2021 | -0.54 | -0.59 | 8.09% | 20.59% | 20.66M | 26.104M | -20.86% | 0.24% |
| Q3 2021 | -0.51 | -0.62 | 17.76% | 20.31% | 23.23M | 26.024M | -10.74% | 16.32% |
| Q2 2021 | -0.62 | -0.57 | -9.72% | -1.64% | 22.44M | 30.263M | -25.85% | -1.01% |
| Q1 2021 | -0.58 | -0.58 | 0.24% | -1.75% | 20.02M | 26.243M | -23.71% | -21.18% |
| Q4 2020 | -0.68 | -0.66 | -2.56% | - | 20.61M | 19.519M | 5.59% | - |
| Q3 2020 | -0.64 | -0.64 | -0.05% | - | 19.97M | 17.512M | 14.04% | - |
| Q2 2020 | -0.61 | -0.65 | 6.47% | - | 22.67M | 18.04M | 25.67% | - |
| Q1 2020 | -0.57 | -0.67 | 14.52% | - | 25.4M | 21.657M | 17.28% | - |
Notes
HERON THERAPEUTICS INC (HRTX) last reported earnings on 2/26/2026.
HERON THERAPEUTICS INC (HRTX) beat EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, HERON THERAPEUTICS INC (HRTX) has beaten EPS estimates in 2 out of 4 releases.